BYHEALTH CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.65 CNY | +1.56% |
|
-4.46% | -8.10% |
| Apr. 25 | Byhealth Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 12 | Byhealth Co., Ltd Approves Cash Dividend for the Year 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 25,779 | 38,182 | 45,840 | 38,801 | 28,964 | 26,618 | - | - |
| Enterprise Value (EV) 1 | 24,518 | 36,602 | 42,971 | 35,861 | 28,964 | 24,523 | 24,410 | 23,739 |
| P/E ratio | -67.9 x | 25.2 x | 25.7 x | 28.2 x | 16.5 x | 13.8 x | 11.7 x | 10.8 x |
| Yield | 2.21% | 2.9% | 2.6% | 0.79% | 5.28% | 4.92% | 4.72% | 5.69% |
| Capitalization / Revenue | 4.9 x | 6.26 x | 6.17 x | 4.94 x | 3.08 x | 2.57 x | 2.29 x | 2.12 x |
| EV / Revenue | 4.66 x | 6.01 x | 5.78 x | 4.56 x | 3.08 x | 2.37 x | 2.1 x | 1.89 x |
| EV / EBITDA | -114 x | 18.4 x | 19.2 x | 19.7 x | 12.6 x | 9.52 x | 8.02 x | 7.17 x |
| EV / FCF | 20.3 x | - | 27.5 x | 31.6 x | - | 174 x | 16.4 x | 10.6 x |
| FCF Yield | 4.91% | - | 3.63% | 3.17% | - | 0.57% | 6.09% | 9.47% |
| Price to Book | 4.3 x | 5.51 x | 4.37 x | 3.63 x | 2.38 x | 2.12 x | 1.95 x | 1.88 x |
| Nbr of stocks (in thousands) | 1,582,493 | 1,581,021 | 1,700,309 | 1,700,322 | 1,700,763 | 1,700,823 | - | - |
| Reference price 2 | 16.29 | 24.15 | 26.96 | 22.82 | 17.03 | 15.65 | 15.65 | 15.65 |
| Announcement Date | 2/28/20 | 3/5/21 | 3/4/22 | 3/17/23 | 2/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,262 | 6,095 | 7,431 | 7,861 | 9,407 | 10,357 | 11,630 | 12,529 |
| EBITDA 1 | -215.1 | 1,995 | 2,243 | 1,823 | 2,295 | 2,576 | 3,045 | 3,309 |
| EBIT 1 | -465.4 | 1,789 | 2,027 | 1,609 | 2,069 | 2,228 | 2,672 | 2,870 |
| Operating Margin | -8.85% | 29.35% | 27.27% | 20.47% | 21.99% | 21.51% | 22.98% | 22.9% |
| Earnings before Tax (EBT) 1 | -424.9 | 1,769 | 2,178 | 1,705 | 2,196 | 2,403 | 2,832 | 3,084 |
| Net income 1 | -355.9 | 1,524 | 1,754 | 1,386 | 1,746 | 1,937 | 2,269 | 2,476 |
| Net margin | -6.76% | 25.01% | 23.6% | 17.63% | 18.56% | 18.7% | 19.51% | 19.77% |
| EPS 2 | -0.2400 | 0.9600 | 1.050 | 0.8100 | 1.030 | 1.132 | 1.341 | 1.448 |
| Free Cash Flow 1 | 1,205 | - | 1,560 | 1,136 | - | 141 | 1,487 | 2,247 |
| FCF margin | 22.9% | - | 20.99% | 14.45% | - | 1.36% | 12.79% | 17.93% |
| FCF Conversion (EBITDA) | - | - | 69.55% | 62.32% | - | 5.47% | 48.84% | 67.91% |
| FCF Conversion (Net income) | - | - | 88.94% | 81.98% | - | 7.28% | 65.54% | 90.73% |
| Dividend per Share 2 | 0.3600 | 0.7000 | 0.7000 | 0.1800 | 0.9000 | 0.7700 | 0.7380 | 0.8900 |
| Announcement Date | 2/28/20 | 3/5/21 | 3/4/22 | 3/17/23 | 2/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,403 | 2,280 | 1,941 | 1,939 | 1,702 | 3,108 | 2,488 | 2,186 | 2,646 | 2,753 | 2,419 | 1,797 | 3,793 | 3,036 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | 32.35 | 821.5 | 430.2 | 519.7 | -162.2 | 1,286 | 563.3 | 415 | - | - | - | - | - | - |
| Operating Margin | 2.31% | 36.03% | 22.17% | 26.8% | -9.53% | 41.38% | 22.64% | 18.98% | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/4/22 | 4/28/22 | 8/5/22 | 10/25/22 | 3/17/23 | 4/26/23 | 8/4/23 | 10/24/23 | 4/25/24 | - | - | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 1,261 | 1,579 | 2,870 | 2,941 | - | 2,095 | 2,208 | 2,879 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 1,205 | - | 1,560 | 1,136 | - | 141 | 1,487 | 2,247 |
| ROE (net income / shareholders' equity) | -6.5% | 24% | 20.1% | 13.5% | 15.3% | 15.3% | 16.5% | 17.2% |
| ROA (Net income/ Total Assets) | -3.93% | 17% | 15.5% | 10.6% | - | 12.1% | 13.1% | 13.6% |
| Assets 1 | 9,060 | 8,986 | 11,303 | 13,062 | - | 15,964 | 17,259 | 18,254 |
| Book Value Per Share 2 | 3.790 | 4.390 | 6.170 | 6.290 | 7.150 | 7.390 | 8.040 | 8.330 |
| Cash Flow per Share 2 | 0.9700 | 0.9900 | 1.090 | 0.8100 | 1.210 | 1.110 | 1.410 | 1.470 |
| Capex 1 | 332 | 319 | 259 | 243 | 1,257 | 689 | 584 | 382 |
| Capex / Sales | 6.3% | 5.24% | 3.48% | 3.09% | 13.36% | 6.65% | 5.02% | 3.05% |
| Announcement Date | 2/28/20 | 3/5/21 | 3/4/22 | 3/17/23 | 2/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.65
CNY
Average target price
22.99
CNY
Spread / Average Target
+46.91%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.10% | 3.67B | |
| +8.20% | 7.78B | |
| +1.64% | 7.38B | |
| +10.20% | 6.52B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M | |
| -16.45% | 802M | |
| +0.32% | 711M |
- Stock Market
- Equities
- 300146 Stock
- Financials Byhealth Co., Ltd
